Spyropoulos Alex C
Lovelace Sandia Health Systems, Clinical Thrombosis Center, 5400 Gibson Blvd SE, Albuquerque, NM 87108, USA.
J Thromb Thrombolysis. 2006 Feb;21(1):91-4. doi: 10.1007/s11239-006-5583-8.
The management of patients on chronic oral anticoagulant therapy, namely Vitamin K antagonists such as warfarin, is often associated with difficult and challenging issues for the healthcare practitioner. Many of these issues, such as warfarin failure or resistance, the optimal warfarin initiation dose, the optimal target International Normalized Ratio in antiphospholipid syndrome, the optimal monitoring frequency and use of point-of-care monitoring, the management of oral anticoagulation during invasive procedures, and the management of over-anticoagulation, have not been evaluated in rigorously-designed clinical trials. The latest American College of Chest Physician recommendations concerning these issues are Grade 2C, the weakest recommendations available. It remains up to the experience and expertise of the individual practitioner along with whatever clinical evidence is available in a particular healthcare environment-especially one associated with an anticoagulant management service-to implement management strategies with respect to these issues in patients on oral anticoagulation.
对接受慢性口服抗凝治疗的患者,即使用华法林等维生素K拮抗剂进行治疗的患者进行管理,对医疗从业者来说往往涉及诸多困难且具有挑战性的问题。其中许多问题,如华法林治疗失败或抵抗、华法林起始最佳剂量、抗磷脂综合征中最佳国际标准化比值目标、最佳监测频率及即时检测的应用、侵入性操作期间口服抗凝的管理以及抗凝过度的管理等,尚未在设计严谨的临床试验中得到评估。美国胸科医师学会关于这些问题的最新建议为2C级,是现有最弱的建议。在特定医疗环境中,尤其是设有抗凝管理服务的环境下,具体管理策略的实施仍取决于个体从业者的经验和专业知识以及可得的临床证据,以便对口服抗凝治疗的患者就这些问题进行管理。